# Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

> **NCT02419287** · PHASE2 · COMPLETED · sponsor: **University of Milano Bicocca** · enrollment: 12 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive

## Interventions

- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT02419287
- **Lead sponsor:** University of Milano Bicocca
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419287, "Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02419287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*